Overview

This is a summary of the European public assessment report (EPAR) for Ibandronic Acid Sandoz. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ibandronic Acid Sandoz.

Ibandronic Acid Sandoz is a medicine that contains the active substance ibandronic acid. It is available as tablets (50 mg).

Ibandronic Acid Sandoz is a ‘generic medicine’. This means that Ibandronic Acid Sandoz is similar to a ‘reference medicine’ already authorised in the European Union (EU). The reference medicine for Ibandronic Acid Sandoz is Bondronat.

Ibandronic Acid Sandoz is used to prevent ‘skeletal events’ (fractures [broken bones] or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone).

The medicine can only be obtained with a prescription.

The recommended dose is one tablet taken once a day. The tablets must always be taken after the patient has fasted overnight for at least six hours and at least 30 minutes before the first food or drink of the day.

Ibandronic Acid Sandoz must be taken with a full glass of plain water (but not mineral water) while standing or sitting up, and the tablets should not be chewed, sucked or crushed. The patient must also not lie down for one hour after taking the tablets.

The active substance in Ibandronic Acid Sandoz, ibandronic acid, is a bisphosphonate. It stops the action of osteoclasts, the cells in the body that are involved in breaking down the bone tissue. This leads to less bone loss. The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.

Because Ibandronic Acid Sandoz is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine. Medicines are bioequivalent when they produce the same levels of the active substance in the body.

Because Ibandronic Acid Sandoz is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

The CHMP concluded that, in accordance with EU requirements, Ibandronic Acid Sandoz has been shown to have comparable quality and to be bioequivalent to Bondronat. Therefore, the CHMP’s view was that, as for Bondronat, the benefit outweighs the identified risk. The Committee recommended that Ibandronic Acid Sandoz be given marketing authorisation.

A risk management plan has been developed to ensure that Ibandronic Acid Sandoz is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ibandronic Acid Sandoz, including the appropriate precautions to be followed by healthcare professionals and patients.

The European Commission granted a marketing authorisation valid throughout the EU for Ibandronic Acid Sandoz on 26 July 2011.

For more information about treatment with Ibandronic Acid Sandoz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Ibandronic Acid Sandoz : EPAR - Summary for the public

български (BG) (107.72 KB - PDF)
español (ES) (78.69 KB - PDF)
čeština (CS) (125.17 KB - PDF)
dansk (DA) (101.24 KB - PDF)
Deutsch (DE) (103.23 KB - PDF)
eesti keel (ET) (100.85 KB - PDF)
ελληνικά (EL) (106.25 KB - PDF)
français (FR) (101.62 KB - PDF)
hrvatski (HR) (98.58 KB - PDF)
italiano (IT) (78.79 KB - PDF)
latviešu valoda (LV) (122.68 KB - PDF)
lietuvių kalba (LT) (101.29 KB - PDF)
magyar (HU) (121.2 KB - PDF)
Malti (MT) (126.79 KB - PDF)
Nederlands (NL) (80.44 KB - PDF)
polski (PL) (126.92 KB - PDF)
português (PT) (101.05 KB - PDF)
română (RO) (98.41 KB - PDF)
slovenčina (SK) (101.9 KB - PDF)
slovenščina (SL) (96.64 KB - PDF)
Suomi (FI) (79.28 KB - PDF)
svenska (SV) (78.92 KB - PDF)

Product information

Ibandronic acid Sandoz : EPAR - Product Information

български (BG) (246.53 KB - PDF)
español (ES) (195.73 KB - PDF)
čeština (CS) (216.13 KB - PDF)
dansk (DA) (190.77 KB - PDF)
Deutsch (DE) (202.58 KB - PDF)
eesti keel (ET) (183.72 KB - PDF)
ελληνικά (EL) (230.97 KB - PDF)
français (FR) (201.39 KB - PDF)
hrvatski (HR) (200.45 KB - PDF)
íslenska (IS) (194.81 KB - PDF)
italiano (IT) (209.83 KB - PDF)
latviešu valoda (LV) (206.94 KB - PDF)
lietuvių kalba (LT) (211.61 KB - PDF)
magyar (HU) (210.33 KB - PDF)
Malti (MT) (242.85 KB - PDF)
Nederlands (NL) (199.47 KB - PDF)
norsk (NO) (191.18 KB - PDF)
polski (PL) (219.5 KB - PDF)
português (PT) (199.92 KB - PDF)
română (RO) (230.13 KB - PDF)
slovenčina (SK) (222.16 KB - PDF)
slovenščina (SL) (201.67 KB - PDF)
Suomi (FI) (190.31 KB - PDF)
svenska (SV) (179.3 KB - PDF)

Latest procedure affecting product information: N/0021

06/07/2022

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Ibandronic acid Sandoz : EPAR - All Authorised presentations

български (BG) (95.25 KB - PDF)
español (ES) (27.53 KB - PDF)
čeština (CS) (93.3 KB - PDF)
dansk (DA) (23.73 KB - PDF)
Deutsch (DE) (26.86 KB - PDF)
eesti keel (ET) (27.06 KB - PDF)
ελληνικά (EL) (94.83 KB - PDF)
français (FR) (27.89 KB - PDF)
íslenska (IS) (27.78 KB - PDF)
italiano (IT) (27.37 KB - PDF)
latviešu valoda (LV) (92.75 KB - PDF)
lietuvių kalba (LT) (91.62 KB - PDF)
magyar (HU) (93.55 KB - PDF)
Malti (MT) (92.24 KB - PDF)
Nederlands (NL) (26.83 KB - PDF)
norsk (NO) (27.15 KB - PDF)
polski (PL) (57.26 KB - PDF)
português (PT) (27.21 KB - PDF)
română (RO) (91.03 KB - PDF)
slovenčina (SK) (57.45 KB - PDF)
slovenščina (SL) (27.04 KB - PDF)
Suomi (FI) (27.28 KB - PDF)
svenska (SV) (27.72 KB - PDF)

Product details

Name of medicine
Ibandronic Acid Sandoz
Active substance
ibandronic acid
International non-proprietary name (INN) or common name
ibandronic acid
Therapeutic area (MeSH)
  • Breast Neoplasms
  • Neoplasm Metastasis
  • Fractures, Bone
Anatomical therapeutic chemical (ATC) code
M05BA06

Pharmacotherapeutic group

  • Drugs for treatment of bone diseases
  • Bisphosphonates

Therapeutic indication

Ibandronic acid Sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Authorisation details

EMA product number
EMEA/H/C/002367

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Sandoz GmbH

Biochemiestrasse 10
6250 Kundl
Austria

Opinion adopted
17/02/2011
Marketing authorisation issued
26/07/2011
Revision
9

Assessment history

Ibandronic acid Sandoz : EPAR - Procedural steps taken and scientific information after authorisation

Ibandronic acid Sandoz : EPAR - Public assessment report

CHMP summary of positive opinion for Ibandronic Acid Sandoz

This page was last updated on

How useful do you find this page?